Sai Parenterals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fgoca0hn0y2lk6fhbum8615s.pdf

Key Takeaways


Gross Margin & Profitability

Anil Kumar Karusala: "This quarter was, the gross margin was the hero of this, this quarter, according to me. As I said to you in my opening remarks, we have worked very thoroughly on the inventory management, and it's just the beginning. We are going to work through that a lot in the next two, three quarters."

Revenue Build & Export Mix

Mark Thulborne: "These are renewals earned through years of consistency and delivering in one of the most tightly regulated markets in the world."

Capacity Expansion & Capex Cycle

Anil Kumar Karusala: "FY27 remains a year of building, and FY28 is when the results of that building should start to show in our performance."

Acquisitions & R&D Build-out

Anil Kumar Karusala: "It's a self-sufficient and it becomes a revenue model, cost center revenue model."

Balance Sheet & Cash Flow


Management Bandwidth & Strategic Direction

Anil Kumar Karusala: "I'm preparing the entire team at all levels, be it at Saicriti, be it at Sai Australia. We're doing everything to ramp up the bandwidth of the management, to take up the individual responsibilities. And I myself want to focus more on the strategy, not on everyday business."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue"Very, very comfortably" cross ₹750 croresFY27 full year
FY27 EBITDA marginComfortably above ~17%FY27 full year
Gross margin floorAbove 45% in all coming quartersAll coming quarters
Unit III expansionNew block commences; most additional volume to Australia/NZDecember 2026
Adelaide facility commissioningCommissioning; TGA inspection in Q2 FY27; commercial supply after license grantJanuary 2027
Saicriti facility completionCompletion; accreditation within ~12 months; exports from FY28, Europe from FY29July 2027
Sai Prathyak third-party contractsBegin signing R&D/CRO contracts; revenue from FY28Q3 FY27
Domestic branded generic receivablesReduce to less than 120 days across the boardNext 2–3 quarters
Philippines anti-TB contractCommercials startAfter January 2027
FY28 guidance releaseFull FY28 guidance providedNext earnings call (Jan/Feb)
US FDA launchNo launch for at least 2–3 years; option open for CMO clientsAt least 2–3 years
Debt trajectoryFY27 peak debt year; debt to come down from FY28/FY29FY28 onward

Key Metrics

MetricQ2 FY27
Revenue from operations₹196.1 cr, +9% QoQ
H1 FY27 revenue₹376.0 cr, ~50% of FY27 target of ₹750 cr
Gross margin47.5%, up from 40.9% in Q1 FY27
EBITDA₹41.4 cr, +67.4% QoQ
EBITDA margin21.1%, up from 13.7% in Q1 FY27 (restated)
H1 FY27 EBITDA margin17.6%, ahead of ~17% full-year guidance
Profit after tax₹10.5 cr, +32.7% QoQ; PAT margin 5.4%
H1 FY27 PAT₹18.4 cr
Depreciation and amortization₹25.1 cr, up from ₹8.1 cr in Q1 FY27
Finance cost₹9 cr, down from ₹9.4 cr in Q1 FY27
Total borrowings₹357 cr at 30 Sep 2026, vs ~₹320 cr at Mar 2026
Cash and cash equivalents₹129 cr at 30 Sep 2026
CDMO share of revenue~73% of Q2 revenue; branded generics ~27%
Exports share of revenue~73% of Q2 revenue
Australia share of export revenue76%, vs 83% in Q1 FY27
Philippines share of export revenue16%, up from 12% in Q1 FY27
Receivables~₹250 cr in H1 FY27; export/CDMO aging <120 days, domestic branded generics 130–150 days
Noumed contracted Australia OTC supplyAUD 23.2 cr (~₹1,506 cr), across EBOS and Wesfarmers renewals
Saicriti injectable capacity target~15.47 cr units, ~47% more than Units I & II upgrade would have delivered
Unit III capacity increase81%, from 8.55 cr to 15.5 cr units per month
Sai Prathyak molecules and SKUs174 molecules, 285 SKUs across critical care and oncology
In-house dossiers98 developed, 45 commercialized, 76 under development for FY28